new-kit-box new-kit-box new-kit-box new-kit-box new-kit-box new-kit-box

Functionally Tested Primary Effector Cells for MoA-Based Cell Killing Bioassays

  • Human PBMCs, ADCC-qualified
  • Human CD8+ T cells, TDCC-qualified
  • Human macrophages, ADCP-qualified
  • Functionally tested with HiBiT TCK lines

Human Macrophages, ADCP-Qualified

  Catalog No. Product Name   Size Price Qty  
CS3055C02 Early Access Human Macrophages, ADCP-Qualified, 1X View Specifications 1 each     Consultar Precio
CS3055C03 Early Access Human Macrophages, ADCP-Qualified, 5X View Specifications 1 each     Consultar Precio

Early Access = This product is available under our Early Access program - Learn More

Catalog (FT) = This product is available under our Catalog (FT) program - Learn More

Human T Cell (CD8+), TDCC-Qualified

  Catalog No. Product Name   Size Price Qty  
CS3055B03 Early Access Human T Cell (CD8+), TDCC-Qualified View Specifications 1 each     Consultar Precio
CS3055B06 Early Access Human T Cell (CD8+) TDCC-Qualified 5X View Specifications 1 each     Consultar Precio

Early Access = This product is available under our Early Access program - Learn More

Catalog (FT) = This product is available under our Catalog (FT) program - Learn More

Human PBMC, ADCC-Qualified

  Catalog No. Product Name   Size Price Qty  
CS3055A15 Early Access Human PBMC, ADCC-Qualified View Specifications 1.0ml     Consultar Precio
CS3055A18 Early Access Human PBMC, ADCC-Qualified 5X View Specifications 1 each     Consultar Precio

Early Access = This product is available under our Early Access program - Learn More

Catalog (FT) = This product is available under our Catalog (FT) program - Learn More

Overview
Protocols
Specifications
Resources
Related Products

Qualified Primary Cells: Minimize Variability, Enhance Reliability

Promega primary effector cells provide a consistent and robust method for target cell killing. Our primary cells are biologically relevant and MoA-qualified for either ADCC, ADCP or TDCC activity to measure the potency and stability of antibodies and other biologics that specifically bind and activate their respective effector cells. These primary effector cells are functionally tested with our HiBiT Target Cell Killing Bioassays, where upon lysis of the target cells and addition of detection reagent, specific cell killing of the target cell is measured by a bright, bioluminescent signal.

Human PBMC, ADCC-Qualified:
Eliminate the Uncertainty and Variability of Primary Cell-Based ADCC Assays

Our thaw-and-use ADCC-Qualified PBMCs provide consistency and robustness for measuring antibody-dependent cellular cytotoxicity. The PBMCs are available in two product formats: as standalone vials or bioassay kits.

Standalone Human PBMC, ADCC-Qualified Cells

  • Single-donor-derived PBMC lots
  • FcγR-genotyped for FcγRIIIa and FcγRIIa
  • ADCC-qualified with HiBiT target cell lines
  • Thaw-and-use: No culture required
Graphical depiction of representative cellular profiles of ADCC-qualified PBMC donors.

Representative cellular profiles of ADCC-qualified PBMC donors. Our lots of PBMCs reflect the donor-to-donor variability expected in these sample types. This variability is crucial for understanding real-world immune responses when developing therapeutics.


PBMC ADCC Bioassay: PBMCs Paired with a Selection of HiBiT Target Cell Killing Bioassays

The PBMC ADCC Bioassay provides ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. The bioassay is simple, homogenous, highly sensitive and provides a robust assay window.

Line graph illustrating that HiBiT TCK Bioassays reflect the ADCC MoA of biologic drugs and demonstrate specificity for cell surface antigens.

In addition to FcyR genotyping, our bioassay kits are functionally tested using our HiBiT Target Cells to demonstrate ADCC activity. Representative bioassay data using our Raji (HiBiT) Target Cells are shown.

Click on your target cell of interest to find the PBMC ADCC Bioassay for you:

RajiRamosH929SK-BR-3, A549, SKOV3

Each PBMC Bioassay kit includes Human PBMCs, ADCC-Qualified; selected Target Cells; RPMI 1640 Media; Fetal Bovine Serum; and Bio-Glo-NB™ TCK Luciferase Assay System.

Human T Cell (CD8+), TDCC-Qualified: Improve Your T Cell Cytotoxicity Assays

Our TDCC-qualified CD8+ T cells provide consistency and robustness for measuring T cell-dependent cellular cytotoxicity. The T cells are available in two product formats: as standalone vials or in a bioassay kit.

Standalone Human T Cell (CD8+), TDCC-Qualified Cells

  • Single-donor-derived T cells
  • TDCC-qualified with HiBiT target cell lines
  • Thaw-and-use: No culture required

Each Donor is Characterized for CD8+ T Cell Purity Following Expansion

Depiction of representative purity of CD8 T Cells (TDCC-Qualified).

Representative profile of CD8 T Cells (TDCC-Qualified). Cells were thawed and stained with antibodies against CD3 and CD8+ (or isotype controls.) Cell populations are >98% CD8+ T Cells.


CD8+ TDCC Bioassay: CD8+ T Cells Paired with a Selection of HiBiT Target Cell Killing Bioassays

The CD8+ TDCC Bioassay, using engineered HiBiT target cells, measures the antibody potency and specific target cell killing. The bioassay is simple, homogenous, highly sensitive and provides a robust assay window.

Line graph illustrating that HiBiT TCK Bioassays reflect the TDCC MOA of biologic drugs and demonstrate specificity for cell surface antigens.

Our bioassay kits are functionally tested using our HiBiT Target Cells to demonstrate TDCC activity. Representative assay data using our Raji (HiBiT) Target Cells are shown.

Click on your target cell of interest to find the CD8+ TDCC Bioassay for you:

RajiRamosH929SK-BR-3, A549, SKOV3

Each TDCC Bioassay kit includes Human CD8+ T cells, TDCC-Qualified; selected Target Cells; RPMI 1640 Media; Fetal Bovine Serum; and Bio-Glo-NB™ TCK Luciferase Assay System.

Human Macrophages, ADCP-Qualified: Off-the-Shelf Primary Macrophage

Our ADCP-qualified primary macrophage provide consistency and robustness for measuring antibody-dependent cellular phagocytosis. The macrophage are available as standalone thaw-and-use vials.




Image of Human Macrophages (ADCP-Qualified).

Standalone Human Macrophages, ADCP-Qualified Cells

  • Derived from primary human monocytes
  • Optimized for ADCP activity with HiBiT target cells
  • Large batch sizes for consistent performance
  • High viability (>95%) and flexible phenotype after thaw
  • Loss-of-signal assay correlates with macrophage ADCP mechanism of action
Upregulated Downregulated No Change
HLA-DR CD68 FcγRII
CD80   FcγRIII
CD86   CD163
CCR7   CD206
CD40   SIRPα
FcγRI    

Human Macrophages (ADCP-Qualified) were thawed and cultured overnight with 50ng/ml IFNγ. Images were collected on an EVOS M5000. The table shows cellular markers that are upregulated/downregulated/unchanged after IFNγ treatment, relative to expression immediately after thaw.


Antibody-dependent cellular phagocytosis data of Promega thaw-and-use primary macrophage.
Antibody-dependent cellular phagocytosis data of monocyte-derived macrophage.

Our thaw-and-use primary macrophage (left panel) provide a quality of antibody-dependent cellular phagocytosis data that is consistent with or better than what researchers see using other sources of macrophage, such as monocyte-derived (right panel).

Protocols

No protocols available

Specifications

Catalog Number:

Contenido

Item Part # Presentación

Human Macrophages (ADCP-Qualified)

CS3055C01 1 × 0.5ml

Certificado de Análisis

Search by lot number

Condiciones de Almacenaje

XX

Patentes y Exclusiones

Promega Cell Line Limited Use Label License (LULL)


BY USE OF THIS MATERIAL, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE.


  • 1. Usage and Transfer Restrictions:
    • 1.1. Recipient may use this material for research use only, which includes but is not limited to drug discovery and development, quality assurance testing and product release assays. No transfer, resale or commercial use of this material is allowed without the written consent of Promega Corporation.
    • 1.2. “Commercial use” means any and all uses of this material or derivatives by recipient for monetary or other consideration, including product manufacture, providing a service, information or data to unaffiliated third parties and resale of the material for any use.
  • 2. Modification Restrictions:
    • 2.1. Recipient shall have no right to modify, derivatize or otherwise create variations of the nucleotide sequence of any proprietary gene, including but not limited to luciferase, NanoBiT® technology (e.g., HiBiT), HaloTag® technology or genes stably transfected within the cells.
    • 2.2. Recipient shall have no right to genetically engineer or otherwise modify the cell line.
  • 3. Propagation and Storage:
    • 3.1. The recipient may not propagate the cells, unless material is marked as Propagation Model, Cell Bank or Master Cell Bank; then recipient may propagate and store the cells for long-term use.
  • 4. For all determinations of luminescence or other assay-related activity of this material and its derivatives, recipient must either:
    • 4.1. Use the detection systems specified in the protocol or data report and purchased from Promega for all luminescence assays when using this material; or
    • 4.2. Contact Promega to obtain a license for use of this material with reagents other than a Bio-Glo™ branded luciferase reagent, including but not limited to:
      • 4.2.1 Bio-Glo™, Bio-Glo-NL™, Bio-Glo-NB™ TCK, Bio-Glo-NB™ VLP, Bio-Glo-NB™ Lytic
  • 5. For uses of this material for energy transfer (such as bioluminescence resonance energy transfer), recipient must:
    • 5.1. Use NanoBRET™-branded luminescent assay reagents (LARs; e.g., NanoBRET™ Nano-Glo® Substrate), Intracellular TE Nano-Glo® Substrate/Inhibitor or Intracellular TE Nano-Glo® Vivazine™/Inhibitor for all determinations of luminescent activity by this material and its derivatives; and
    • 5.2. Use NanoBRET™-branded energy acceptors (e.g., NanoBRET™ tracers, NanoBRET™ dyes, BRET-optimized HaloTag® ligands) for all determinations of energy transfer activity by this material and its derivatives; or
    • 5.3. Contact Promega to obtain a license for the use of the material and its derivatives for energy transfer assays to energy acceptors not manufactured by Promega. No license is needed if the energy transfer acceptor is a genetically encoded autofluorescent protein.
  • 6. For uses of HaloTag® Technology in this material, recipient must either:
    • 6.1. Use Promega HaloTag® ligands, which can be modified or linked to Promega or customer-supplied moieties; or
    • 6.2. Contact Promega to obtain a license if Promega HaloTag® ligands are not to be used.
  • 7. Disclaimer and Governing Law:
    • 7.1. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH REGARD TO THE MATERIAL. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.

Contenido

Item Part # Presentación

Human Macrophages (ADCP-Qualified)

CS3055C01 5 × 0.5ml

Certificado de Análisis

Search by lot number

Condiciones de Almacenaje

XX

Patentes y Exclusiones

Promega Cell Line Limited Use Label License (LULL)


BY USE OF THIS MATERIAL, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE.


  • 1. Usage and Transfer Restrictions:
    • 1.1. Recipient may use this material for research use only, which includes but is not limited to drug discovery and development, quality assurance testing and product release assays. No transfer, resale or commercial use of this material is allowed without the written consent of Promega Corporation.
    • 1.2. “Commercial use” means any and all uses of this material or derivatives by recipient for monetary or other consideration, including product manufacture, providing a service, information or data to unaffiliated third parties and resale of the material for any use.
  • 2. Modification Restrictions:
    • 2.1. Recipient shall have no right to modify, derivatize or otherwise create variations of the nucleotide sequence of any proprietary gene, including but not limited to luciferase, NanoBiT® technology (e.g., HiBiT), HaloTag® technology or genes stably transfected within the cells.
    • 2.2. Recipient shall have no right to genetically engineer or otherwise modify the cell line.
  • 3. Propagation and Storage:
    • 3.1. The recipient may not propagate the cells, unless material is marked as Propagation Model, Cell Bank or Master Cell Bank; then recipient may propagate and store the cells for long-term use.
  • 4. For all determinations of luminescence or other assay-related activity of this material and its derivatives, recipient must either:
    • 4.1. Use the detection systems specified in the protocol or data report and purchased from Promega for all luminescence assays when using this material; or
    • 4.2. Contact Promega to obtain a license for use of this material with reagents other than a Bio-Glo™ branded luciferase reagent, including but not limited to:
      • 4.2.1 Bio-Glo™, Bio-Glo-NL™, Bio-Glo-NB™ TCK, Bio-Glo-NB™ VLP, Bio-Glo-NB™ Lytic
  • 5. For uses of this material for energy transfer (such as bioluminescence resonance energy transfer), recipient must:
    • 5.1. Use NanoBRET™-branded luminescent assay reagents (LARs; e.g., NanoBRET™ Nano-Glo® Substrate), Intracellular TE Nano-Glo® Substrate/Inhibitor or Intracellular TE Nano-Glo® Vivazine™/Inhibitor for all determinations of luminescent activity by this material and its derivatives; and
    • 5.2. Use NanoBRET™-branded energy acceptors (e.g., NanoBRET™ tracers, NanoBRET™ dyes, BRET-optimized HaloTag® ligands) for all determinations of energy transfer activity by this material and its derivatives; or
    • 5.3. Contact Promega to obtain a license for the use of the material and its derivatives for energy transfer assays to energy acceptors not manufactured by Promega. No license is needed if the energy transfer acceptor is a genetically encoded autofluorescent protein.
  • 6. For uses of HaloTag® Technology in this material, recipient must either:
    • 6.1. Use Promega HaloTag® ligands, which can be modified or linked to Promega or customer-supplied moieties; or
    • 6.2. Contact Promega to obtain a license if Promega HaloTag® ligands are not to be used.
  • 7. Disclaimer and Governing Law:
    • 7.1. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH REGARD TO THE MATERIAL. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.

Certificado de Análisis

Search by lot number

Condiciones de Almacenaje

XX

Certificado de Análisis

Search by lot number

Condiciones de Almacenaje

XX

Certificado de Análisis

Search by lot number

Condiciones de Almacenaje

XX

Certificado de Análisis

Search by lot number

Condiciones de Almacenaje

XX

Resources

Cell Therapy: Decoding CAR-T

CAR-T cellular immunotherapy is a groundbreaking cancer treatment that uses genetically reprogrammed T-cells to target and destroy cancer cells. Watch this video to learn more about CAR-T cellular immunotherapy and how it is revolutionizing the world of cancer treatment.